NCT02307227View on ClinicalTrials.gov

Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2014

Conditions
Breast Neoplasms
Interventions
DRUG

Trastuzumab

DRUG

Paclitaxel

DRUG

Epirubicin

DRUG

Docetaxel

Trial Locations (1)

33081

Centro di Riferimento Oncologico, Aviano

All Listed Sponsors
lead

Centro di Riferimento Oncologico - Aviano

OTHER

NCT02307227 - Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors | Biotech Hunter | Biotech Hunter